Can Red Light Therapy Shrink Tumors?

Standard red light therapy, the kind sold as consumer LED panels and used in wellness clinics, does not shrink tumors. No clinical evidence supports using low-level red or near-infrared light on its own to treat cancer. However, light absolutely is used in oncology, just not in the way the wellness industry implies. Photodynamic therapy, a medical procedure that pairs specific wavelengths of light with injected photosensitizing drugs, can destroy certain cancers. The confusion between these two very different uses of light drives much of the misinformation around this topic.

How Red Light Therapy Works at the Cellular Level

When people talk about “red light therapy,” they usually mean photobiomodulation, sometimes abbreviated PBM. This involves exposing the body to low-intensity red or near-infrared light, typically from LEDs, at wavelengths between roughly 600 and 1,000 nanometers. The target inside cells is a specific part of the energy-production machinery in mitochondria: an enzyme called cytochrome c oxidase, which sits in the mitochondrial electron transport chain. When photons hit this enzyme, they knock off a molecule of nitric oxide that normally slows the enzyme down. That speeds up electron transfer, restores the cell’s ability to pump protons across the mitochondrial membrane, and increases ATP production, the universal energy currency of cells.¹ The process also causes a brief spike in reactive oxygen species, molecules that play roles in cell signaling.²

In plain terms, PBM gives cells a metabolic nudge. It helps them produce energy more efficiently and triggers some signaling cascades. That is genuinely useful for wound healing, reducing inflammation, and easing pain, all things where you want cells to work better. But nothing about this mechanism selectively targets cancer cells. PBM energizes whatever cells absorb the light. If anything, giving a metabolic boost to cancer cells would be the last thing you’d want, which is exactly why the safety question matters so much.

Why PBM Alone Does Not Kill Cancer Cells

The mechanism of PBM is fundamentally about stimulation, not destruction. It makes cells function more efficiently rather than damaging or killing them. Cancer cells are, at a basic level, still cells, and they respond to PBM the same way healthy cells do. A preliminary animal study that exposed mice bearing 330 tumors to full-body 670-nanometer LED light twice daily for 37 consecutive days found no measurable effect on tumor growth compared to a control group.³ More recently, an in vitro study testing PBM on squamous cell carcinoma lines found no significant effects on cell proliferation or viability under the experimental conditions used.⁴

This is not surprising when you understand what PBM does. It does not generate the kind of chemical destruction needed to kill a cell. It does not produce enough reactive oxygen species to overwhelm a cell’s defenses, does not heat tissue to damaging temperatures, and does not trigger programmed cell death. Consumer red light panels operate at power levels far too low to do any of those things. The mechanism is pro-metabolic and pro-healing, which is why it is studied for rehabilitation, skin conditions, and pain management. Expecting it to shrink a tumor is like expecting a vitamin supplement to work as chemotherapy.

Photodynamic Therapy Is a Different Treatment Entirely

Where the confusion gets especially thick is with photodynamic therapy, or PDT. PDT does destroy cancer cells using light, and it is a legitimate, clinically approved cancer treatment. But calling it “red light therapy” is like calling surgery “a knife thing.” The light is only one piece of a multi-step medical procedure.

In PDT, a patient first receives a photosensitizing drug, either applied topically or injected intravenously. These drugs accumulate preferentially in rapidly dividing cells, including tumor tissue. When the photosensitizer is then exposed to a specific wavelength of light, it reacts with oxygen in the tissue to produce singlet oxygen, an extremely reactive molecule that tears through cell membranes, mitochondria, and other structures.⁵ The singlet oxygen triggers apoptosis through multiple pathways: it can activate death receptors on the cell surface, disrupt mitochondrial membranes to release proteins that trigger the cell’s self-destruct sequence, cause the endoplasmic reticulum to malfunction, and breach lysosomal membranes. The result is targeted cell death in the treated area.

PDT has shown real clinical results in several cancer types. Non-melanoma skin cancers are treated effectively using topical photosensitizers like methyl aminolevulinate and 5-aminolevulinic acid. In lung cancer, agents like porfimer sodium and chlorin e6 have shown promise in both preclinical and clinical work. For head and neck cancers, PDT has been used as an add-on after surgery, with agents like temoporfin showing potential in early-stage larynx cancer and recurrent tumors.⁶ A study comparing blue and red light for PDT in basal cell carcinoma found complete response rates of 98% for blue light and 93% for red light.⁷

The critical difference is that without the photosensitizing drug, the light alone does nothing therapeutic to the tumor. The drug is what makes the light dangerous to cancer cells. A consumer LED panel, no matter how powerful, cannot replicate PDT because it is missing the entire pharmacological component. Anyone claiming their red light device offers “photodynamic” benefits without a prescription photosensitizer is misrepresenting the science.

Does Red Light Therapy Make Existing Cancers Worse?

If PBM does not shrink tumors, the next logical worry is whether it could feed them. After all, if red light boosts cellular metabolism, wouldn’t a tumor love that extra energy? This concern has been a real barrier to using PBM in oncology settings, even for supportive care. The evidence so far suggests the fear is overblown, but it is not fully settled.

A thorough dosimetric reappraisal examined the five studies most frequently cited as evidence that PBM might stimulate tumor growth. The analysis found that in four of the five, the light doses used were far outside the therapeutic range: surface temperatures reaching 55°C (and in places 71°C), irradiances roughly 25 times what is used clinically, and injuries the original researchers themselves described as coagulation and necrosis. The fifth study, a xenograft model, used a dose within the therapeutic window but relied on immunodeficient mice that cannot mount the immune responses relevant to real-world PBM use. Critically, a sixth study from the same research group, using the same device at a therapeutic irradiance, actually reported therapeutic benefit.⁸

The reappraisal concluded that none of the commonly cited alarm-bell studies provides dosimetrically secure evidence of a hazard from therapeutic-range PBM. But the authors were careful to note that the absence of evidence for harm is not the same as proof of safety. Meanwhile, the animal study mentioned earlier, where 670-nanometer light was delivered to tumor-bearing mice for over a month, found no measurable change in tumor growth.³

There is one area that deserves caution. Research has shown that red and near-infrared light can promote new blood vessel formation by stimulating calcium influx, VEGF production, and nitric oxide generation in endothelial cells, effects that were observed even in the presence of a malignant environment.⁹ Tumor growth often depends on recruiting new blood vessels to feed the growing mass, so light-stimulated blood vessel formation in the vicinity of a tumor is at least a theoretical concern, even if it has not been shown to accelerate tumor growth in living animals at therapeutic doses. For anyone with an active cancer diagnosis, this is exactly the kind of nuance that warrants a conversation with an oncologist before using any red light device.

Where Red Light Actually Helps Cancer Patients

The strongest evidence for PBM in oncology has nothing to do with killing tumors and everything to do with managing treatment side effects. Oral mucositis, the painful mouth sores caused by chemotherapy and radiation, is one of the most common and debilitating complications of cancer treatment. PBM has been shown to be effective enough at preventing it that clinical guidelines now recommend it in specific settings.

A systematic review led to a formal recommendation for low-level laser at 650 nanometers for preventing oral mucositis in adults receiving high-dose chemotherapy before stem cell transplantation. A separate suggestion was made for 632.8-nanometer laser to prevent oral mucositis in patients getting head and neck radiation without concurrent chemotherapy.¹⁰ This is not fringe or experimental. It is guideline-level evidence, the kind of finding robust enough for professional organizations to issue formal recommendations.

A randomized clinical trial found that patients who received PBM preconditioning before chemotherapy fared dramatically better than those who did not. After two weeks, 80 to roughly 87% of patients in the PBM groups remained free of oral mucositis, while 93% of control patients had developed it, with cases ranging from mild redness to ulcers larger than 3 square centimeters.¹¹

PBM also shows promise for radiodermatitis, the skin damage caused by radiation therapy. A systematic review of LED therapy in women with breast cancer undergoing radiation found that treated patients had significantly less severe skin reactions. In one included study, about 95% of the LED group had only minimal skin changes compared to about 14% in the control group. The treatment also reduced the number of radiation treatment interruptions caused by skin damage. However, the benefits were limited to acute radiodermatitis; chronic cases did not improve.¹²

This is the genuine clinical story for red light in cancer care. It does not fight the disease itself. It helps patients tolerate their treatment better, with less pain, fewer sores, and fewer interruptions to their therapy schedule.¹³

The Tissue Penetration Problem

Even if red light could kill cancer cells, there is a basic physics problem: it cannot reach most tumors. Light at red and near-infrared wavelengths penetrates skin and superficial tissue to some degree, but it is absorbed and scattered rapidly. Research on infrared light penetration through the human scalp and skull has shown that a 0.5-watt LED cannot deliver meaningful energy even to the brain sitting just beneath the bone.¹⁴ If light from consumer-grade LEDs cannot reliably pass through a few millimeters of bone, it certainly cannot reach a pancreatic tumor, a liver metastasis, or a lung nodule.

This is why PDT is typically limited to surface-accessible tumors or those reachable by fiber-optic light guides threaded through endoscopes or inserted during surgery. Non-melanoma skin cancers are ideal PDT candidates precisely because the photosensitizer and the light can both reach the tumor easily. For deeper cancers, the light delivery challenge is a major constraint, one that no consumer panel can overcome.

Photothermal Therapy and Newer Light-Based Approaches

Beyond PDT, researchers are exploring other ways to weaponize light against tumors. Photothermal therapy, or PTT, uses nanoparticles that absorb near-infrared light and convert it into heat, essentially cooking tumor cells from the inside. Second near-infrared window photothermal therapy, which uses wavelengths in the 1,000-to-1,700-nanometer range, has attracted particular attention because those longer wavelengths penetrate tissue more deeply and cause less collateral damage.¹⁵

Some approaches combine photothermal therapy with chemotherapy using “switchable” nanoparticles that release cancer drugs when heated by near-infrared light. In mouse models, this combination of heat and drug delivery has produced substantial inhibition of tumor growth.¹⁶ These are sophisticated nanotechnology platforms, not something achievable with an off-the-shelf LED panel. They require engineered nanoparticles injected into the body and precisely targeted light delivery, usually by laser. The technology is promising but still largely preclinical.

Near-Infrared Light as a Surgical Tool

One of the most practical uses of near-infrared light in cancer care has nothing to do with treating tumors and everything to do with finding them. Near-infrared fluorescence-guided surgery uses fluorescent dyes that glow under infrared light to help surgeons see structures they otherwise could not. During lung surgery, for example, the technique can help locate small, non-palpable tumor nodules, identify sentinel lymph nodes, and visualize the boundaries between lung segments during complex resections.¹⁷

In a study of 27 patients with lung tumors of various types, near-infrared fluorescence imaging successfully visualized tumors in about 74% of patients. Perhaps more striking, the method identified tumor foci that were not visible on standard imaging in about 11% of patients, catching disease that might otherwise have been missed.¹⁸ This application uses infrared light purely as an imaging aid. The light illuminates, it does not treat. But for the patient on the operating table, the difference between a surgeon who can see a hidden tumor nodule and one who cannot is meaningful.

What Consumer Red Light Device Makers Get Wrong

The marketing around consumer red light therapy devices frequently blurs the line between PBM and PDT, between animal models and human trials, and between supportive care and treatment. A company might cite a study showing PDT cleared skin cancer and imply that their LED panel offers similar benefits, leaving out that the study involved a prescription photosensitizing drug and medical supervision. Or they might reference PBM’s guideline-level evidence for oral mucositis and present it as proof that red light “fights cancer,” ignoring that the therapy helped patients tolerate cancer treatment rather than treating cancer itself.

Regulatory agencies have focused their enforcement on marketing claims rather than product safety. The concern is not that consumer LED panels are dangerous. At the power levels most home devices operate, they are unlikely to cause harm. The concern is that someone with cancer might delay or refuse proven treatment because they believe a consumer device can substitute for it. The stakes of that misunderstanding are life and death, and the nuances of light-based oncology are easy to misrepresent to a layperson.

If you are considering red light therapy during or after cancer treatment, the most useful framing is this: PBM is a well-studied supportive therapy that can ease treatment side effects like mouth sores and skin damage, and the current evidence does not show that it accelerates tumor growth at therapeutic doses. But it is not a cancer treatment. The light-based therapies that do kill cancer cells, PDT and photothermal therapy, are medical procedures requiring drugs, nanoparticles, or surgical-grade lasers that no consumer device can replicate.